{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:31:04Z","timestamp":1786113064357,"version":"build-2736575974"},"reference-count":27,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,6,2]]},"DOI":"10.1136\/ejhpharm-2026-005003","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:18Z","timestamp":1785950418000},"page":"ejhpharm-2026-005003","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Discordant CYP2C19 genotype-phenotype relationship in voriconazole metabolism: impact of inflammation on drug exposure in a Chinese patient"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5884-1111","authenticated-orcid":false,"given":"Hui Qin","family":"Ang","sequence":"first","affiliation":[{"name":"Pharmacy, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ching","family":"Yuen","sequence":"additional","affiliation":[{"name":"Pharmacy, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026080510200895000_ejhpharm-2026-005003v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw349"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.12.003"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1439586","article-title":"Voriconazole: a review of adjustment programs guided by therapeutic drug monitoring","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.6","unstructured":"Dean L . Voriconazole Therapy and CYP2C19 Genotype. In: Pratt VM , Scott SA , Pirmohamed M , eds. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US), 2012."},{"key":"2026080510200895000_ejhpharm-2026-005003v1.7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharma Therapeutics"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102089","article-title":"Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data","volume":"10","author":"Bolcato","year":"2021","journal-title":"J Clin Med"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.11","unstructured":"Voriconazole, serum. n.d. Available: https:\/\/www.sgh.com.sg\/our-specialties\/pathology\/pathology-lab-services\/voriconazole-serum"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.12","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1111\/bcp.15495","article-title":"Effects of inflammation on voriconazole levels: A systematic review","volume":"88","author":"Li","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.13","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, Voriconazole; 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547891\/"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.14","unstructured":"CYP3A5. n.d. Available: https:\/\/www.clinpgx.org\/gene\/PA131\/haplotype"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.15","unstructured":"CYP3A5 &amp; voriconazole. n.d. Available: https:\/\/www.clinpgx.org\/combination\/PA131,PA10233\/variantAnnotation"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jgar.2019.12.004","article-title":"The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia","volume":"21","author":"Zhou","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.17","unstructured":"Hogan JW . Managing ruxolitinib-associated liver toxicity in patients with myelofibrosis requires a nuanced approach. 2024. Available: https:\/\/dailynews.ascopubs.org\/do\/managing-ruxolitinib-associated-liver-toxicity-patients-myelofibrosis-requires-nuanced"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.18","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, Ruxolitinib; 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548534\/"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-04290-9","article-title":"The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update?","volume":"27","author":"Moreno","year":"2023","journal-title":"Crit Care"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.20","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13120388","article-title":"Sepsis and the Liver","volume":"13","author":"Geladari","year":"2025","journal-title":"Diseases"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/cc11381"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-025-05697-w","article-title":"Factors affecting voriconazole pharmacokinetic variability in critically ill patients: a systematic review","volume":"29","author":"Coste","year":"2025","journal-title":"Crit Care"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.23","doi-asserted-by":"crossref","first-page":"106750","DOI":"10.1016\/j.ijantimicag.2023.106750","article-title":"Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model","volume":"61","author":"van den Born","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03820-14"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.25","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13887","article-title":"Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole","volume":"17","author":"Klomp","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.26","doi-asserted-by":"crossref","first-page":"106692","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026080510200895000_ejhpharm-2026-005003v1.27","doi-asserted-by":"crossref","unstructured":"Lou Y , Wang Y , Liu J , et al . Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort. Antimicrob Agents Chemother 2025;69. doi:10.1128\/aac.00487-25","DOI":"10.1128\/aac.00487-25"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2026-005003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:21Z","timestamp":1785950421000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2026-005003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":27,"alternative-id":["10.1136\/ejhpharm-2026-005003"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2026-005003","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}